As we near the end of week #2, all is well. They did slow the infusion rate from 30 minutes to 1 hour, which reduced the pain & burning sensation at the IV site. It did not, however, totally eliminate it. We found out today that it seems to be common among the participants of this study to experience these effects. I wonder if, perhaps, they might need to give each of them a port to eliminite these complications.
Other than that, John continues to tolerate the drug very well. The only other minor effect is some heartburn, but Zantac takes care of that. He takes it at the first sign of discomfort and it is stopped almost immediately.
So, he has his last treatment of the week tomorrow, after which we'll pack up and head back home. He'll be scanned on the 21st to see how he's progressing. If there is improvement, or even status quo, he will continue in the trial, which means continuing the schedule of one week treatment followed by two weeks off and repeated as such over and over. However, should he have some growth in the cancer, they will re-evaluate and probably pull him from the study and start him on some other chemo treatment. My prayer is that Belinostat is working for him and reducing the cancer.
Nice to hear that belinostat works. What kind of studie yuo are in?
ReplyDeleteThey're trying to figure out the proper dose for people with impaired liver function and needed some people with normal liver function in the study group as well.
ReplyDelete